GH Research (GHRS) Operating Leases (2023 - 2025)

GH Research's (GHRS) quarterly Operating Leases came in at $500000.0 in Q4 2025, up 35.5% year-on-year from $369000.0 in Q4 2024, and up 35.5% quarter-over-quarter from $369000.0 in Q4 2024.

GH Research (GHRS) Operating Leases (2023 - 2025) Analysis & Trends

GH Research's Operating Leases history runs 3 years deep, the most recent figure standing at $500000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases rose 35.5% year-over-year to $500000.0 in Q4 2025; TTM through Dec 2025 was $500000.0, a 35.5% increase from a year earlier, with the FY2025 full-year figure at $500000.0, up 35.5% from the prior year.
  • Operating Leases grew to $500000.0 in Q4 2025 per GHRS's latest filing, from $369000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.0 million in Q4 2023 and bottomed at $369000.0 in Q4 2024.
  • The 3-year median for Operating Leases is $500000.0 (2025), against an average of $623000.0.
  • Across the five-year window, Operating Leases slumped 63.1% in 2024 and surged 35.5% in 2025, its largest moves.
  • Year by year, Operating Leases stood at $1.0 million in 2023, then slumped by 63.1% to $369000.0 in 2024, then soared by 35.5% to $500000.0 in 2025.
  • Per Business Quant, the three latest GHRS Operating Leases figures stand at $500000.0 (Q4 2025), $369000.0 (Q4 2024), and $1.0 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 GH Research 1.69 Bn 1.69 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 500,000.00
Dec 31, 2024 369,000.00
Dec 31, 2023 1.00 Mn